Pathalys Pharma Inc.

$300M raise for rare disease company GondolaBio headlines the week’s biggest venture rounds

With important work ahead for ADC in lung cancer, Gilead strikes co-development deal with Carlyle-owned life sciences firm

With some biopharmas strapped for cash to fund Phase III programs, PE-backed firm’s co-investment fund now supplements co-development fund

Leading $150M round, PE-backed venture firm will draw on clinical expertise of organization set up to advise on late-stage trials

Plus new CEO at Zealand Pharma, updates from Nuvalent, Pathalys and more